Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity


HIV Prevention


Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NN.

External Link:

Link to article


Persons infected with HIV often have altered lipid profiles that may be affected by antiretroviral therapies (ART). Traditional lipid measurements may be insufficient to assess cardiovascular disease (CVD) risk in this population.


We report results from 39 ART-naïve participants in a substudy of A5248, a single-arm study of raltegravir (RAL), emtricitabine/tenofovir administration. Samples were collected at baseline, 12, 24, and 48 weeks after ART initiation. We performed advanced lipid phenotyping using nuclear magnetic resonance spectroscopy (NMR) spectroscopy (Liposcience, Raleigh, NC) for lipid particle size and number, and examined HDL function measuring reverse cholesterol transport using J774 macrophages.


We report significant increases in total cholesterol (TC, 13 mg/dL; p<0.001) and low density lipoprotein (LDL, 8 mg/dL; p=0.03), with no change in triglycerides (TGs) and without an increase in LDL-particle number (p>0.1 all timepoints). High density lipoprotein (HDL) levels were increased over baseline levels at all timepoints (p<0.003), but reached a peak at week 12 and subsequently declined. HDL particle numbers also increased from baseline (p<0.002) and HDL function improved at week 48 (7% increase in efflux capacity; p<0.001). Oxidized LDL (oxLDL) levels decreased by week 12, but rose subsequently, and were not different from baseline at later timepoints.


HDL increases were associated with increases in beneficial HDL particles and HDL cholesterol efflux capacity, which may reduce future CVD events. Persistent inflammation in these HIV+ participants, may be a cause, or consequence of oxLDL levels, and may contribute to declining levels of HDL over time.

Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3091. [Epub ahead of print]
PMID: 27740536



Clinical Trials

A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term...

The study is being done to try to determine which factors contribute to the persistence of HIV (how long the virus remains) in...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More